The AADC Research Trust is committed to achieving due impartiality in all it’s output. This commitment is fundamental to our reputation, our values and the trust of our audience. The term ‘due’ means that the impartiality must be adequate and appropriate to the output, taking account of the subject and nature of the content, the likely audience expectation and any signposting that may influence that expectation.

We endeavour to ensure that it is made clear to our audience when personal opinions or views are expressed.

The AADC Research Trust reports on information ascertained from various trusted sources.

Specifically at this time we are reporting - not advertising or promoting - on AAV2-hAADC Gene Replacement Therapy performed by Professor Krystof Bankiewicz in Poland. It is an ACTIVE treatment based on GT approach developed under NIH grant, approved by the FDA, 2 US IRB’s and constitute experimental treatment to save lives of AADC deficient children.